OncoMatch/Clinical Trials/NCT05105152
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Is NCT05105152 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SC-DARIC33 for acute myeloid leukemia.
Treatment: SC-DARIC33 — A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: CD33 expression (positive by flow cytometry)
AML that expresses CD33 by flow cytometry
Prior therapy
Cannot have received: virotherapy
Lab requirements
Kidney function
serum creatinine ≤ 1.5 x the upper limit of normal (uln)
Liver function
total bilirubin ≤ 3 times uln for age or conjugated bilirubin ≤ 2 mg/dl and alt (sgpt) ≤ 5 times uln
Cardiac function
shortening fraction ≥ 28% or ejection fraction ≥ 50% as measured by echocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Seattle Children's Hospital · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify